Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com



Growth: Bad revenue growth rate -3.5%, there is slowdown compared to average historical growth rates 27.6%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +9.5%

Profitability: LTM EBITDA margin is positive, +26.7%. On average the margin is decreasing unsteadily. Gross margin is high, +79.0%. In the last quarter the company beat the estimated EPS, +4.1%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.11 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 6.3%. Free cash flow yield 10.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 0.3% higher than minimum and 44.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.7x by EV / Sales multiple , the company can be 38.9% undervalued

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+0.3%)44.85
year average price 56.49  


year start price 66.77 2023-04-29

max close price 69.08 2023-05-11

min close price 44.70 2024-04-25

current price 44.85 2024-04-27
Common stocks: 2 111 517 922

Dividend Yield:  6.3%
FCF Yield LTM: 10.5%
EV / LTM EBITDA: 10.1x
EV / EBITDA annualized: 19.6x
Last revenue growth (y/y):  -3.5%
Last growth of EBITDA (y/y):  -64.1%
Historical revenue growth:  27.6%
Historical growth of EBITDA:  15.9%
EV / Sales: 2.7x
Margin (EBITDA LTM / Revenue): 26.7%
Fundamental value created in LTM:
Market Cap ($m): 94 702
Net Debt ($m): 31 427
EV (Enterprise Value): 126 129
Price to Book: 3.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-25Zacks Investment Research

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

2024-04-25Zacks Investment Research

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

2024-04-25The Motley Fool

Why Bristol Myers Squibb Stock Is Sinking Today

2024-04-25InvestorPlace

Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts

2024-04-25Zacks Investment Research

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

2024-04-25Barrons

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts

2024-04-25CNBC

Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss

2024-04-25Market Watch

Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates

2024-04-25Reuters

Bristol Myers posts quarterly loss, revenue rises 5%

2024-04-22Zacks Investment Research

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BMY BMY BMY BMY BMY BMY BMY
reportedCurrency USD USD USD USD USD USD USD
cik 14 272 14 272 14 272 14 272 14 272 14 272 14 272
fillingDate 2024-04-25 2024-02-13 2023-10-26 2023-07-27 2023-04-27 2023-02-14 2022-10-26
acceptedDate 2024-04-25 12:38:46 2024-02-13 11:54:06 2023-10-26 12:33:30 2023-07-27 12:28:24 2023-04-27 11:56:52 2023-02-14 16:24:27 2022-10-26 11:37:24
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 11 865M 11 477M 10 966M 11 226M 11 337M 11 406M 11 218M
costOfRevenue 2 932M 2 745M 2 506M 2 876M 2 566M 2 593M 2 353M
grossProfit 8 933M 8 732M 8 460M 8 350M 8 771M 8 813M 8 865M
grossProfitRatio 0.753 0.761 0.771 0.744 0.774 0.773 0.790
researchAndDevelopmentExpenses 2 695M 2 478M 2 242M 2 258M 2 321M 2 510M 2 418M
generalAndAdministrativeExpenses 0 673M 0 0 0 0 0
sellingAndMarketingExpenses 0 1 400M 2 003M 0 1 762M 2 266M 1 930M
sellingGeneralAndAdministrativeExpenses 2 367M 2 073M 2 003M 1 934M 1 762M 2 266M 1 930M
otherExpenses 0 -272M 565M 526M 2 256M 2 343M 2 308M
operatingExpenses 5 062M 6 829M 4 245M 6 449M 6 339M 7 119M 6 656M
costAndExpenses 7 994M 9 574M 6 751M 9 325M 8 905M 9 712M 9 009M
interestIncome 0 145M 107M 0 0 0 0
interestExpense 0 316M 280M 282M 288M 294M 299M
depreciationAndAmortization 0 2 464M 2 435M 2 257M 2 256M 2 343M 2 588M
ebitda 3 871M 4 148M 4 215M 4 626M 5 096M 4 714M 4 795M
ebitdaratio 0.326 0.361 0.384 0.412 0.450 0.413 0.427
operatingIncome 3 871M 1 684M 4 215M 4 158M 2 840M 2 371M 2 207M
operatingIncomeRatio 0.326 0.147 0.384 0.370 0.251 0.208 0.197
totalOtherIncomeExpensesNet -15 387M 87M -2 078M 240M -70M -512M 2M
incomeBeforeTax -11 516M 1 674M 2 137M 1 859M 2 770M 1 859M 2 209M
incomeBeforeTaxRatio -0.971 0.146 0.195 0.166 0.244 0.163 0.197
incomeTaxExpense 392M -88M 203M -218M 503M -166M 601M
netIncome -11 911M 1 762M 1 928M 2 073M 2 262M 2 022M 1 606M
netIncomeRatio -1.004 0.154 0.176 0.185 0.200 0.177 0.143
eps -5.890 0.870 0.940 0.990 1.080 0.960 0.750
epsdiluted -5.890 0.870 0.930 0.990 1.070 0.950 0.750
weightedAverageShsOut 0 2 027M 2 057M 2 093M 2 099M 2 108M 2 133M
weightedAverageShsOutDil 0 2 033M 2 064M 2 102M 2 113M 2 124M 2 149M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BMY BMY BMY BMY BMY BMY BMY
reportedCurrency USD USD USD USD USD USD USD
cik 14 272 14 272 14 272 14 272 14 272 14 272 14 272
fillingDate 2024-04-25 2024-02-13 2023-10-26 2023-07-27 2023-04-27 2023-02-14 2022-10-26
acceptedDate 2024-04-25 12:38:46 2024-02-13 11:54:06 2023-10-26 12:33:30 2023-07-27 12:28:24 2023-04-27 11:56:52 2023-02-14 16:24:27 2022-10-26 11:37:24
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 9 330M 11 464M 7 514M 8 372M 8 995M 9 123M 7 734M
shortTermInvestments 340M 816M 171M 358M 274M 130M 1 293M
cashAndShortTermInvestments 9 670M 12 280M 7 685M 8 372M 8 995M 9 123M 9 027M
netReceivables 10 447M 15 264M 15 647M 15 059M 13 405M 13 937M 9 613M
inventory 2 985M 2 662M 2 436M 2 364M 2 605M 2 339M 2 074M
otherCurrentAssets 5 567M 1 509M 1 810M 1 868M 1 754M 1 596M 6 082M
totalCurrentAssets 28 669M 31 770M 27 632M 28 074M 27 086M 27 273M 26 796M
propertyPlantEquipmentNet 6 750M 8 036M 7 848M 7 629M 7 605M 7 475M 6 035M
goodwill 21 738M 21 169M 21 147M 21 163M 21 162M 21 149M 21 112M
intangibleAssets 32 760M 27 485M 29 377M 31 773M 34 054M 36 355M 38 179M
goodwillAndIntangibleAssets 54 498M 48 654M 50 524M 52 936M 55 216M 57 504M 59 291M
longTermInvestments 0 2 063M 1 882M 1 991M 2 005M 2 187M 1 959M
taxAssets 2 723M 2 768M 1 514M 1 572M 1 317M 1 344M 1 329M
otherNonCurrentAssets 6 391M 1 868M 1 863M 1 287M 1 052M 1 037M 2 786M
totalNonCurrentAssets 70 362M 63 389M 63 631M 65 415M 67 195M 69 547M 71 400M
otherAssets 0 0 0 0 0 0 0
totalAssets 99 031M 95 159M 91 263M 93 489M 94 281M 96 820M 98 196M
accountPayables 3 539M 3 259M 2 813M 3 069M 3 194M 3 040M 2 595M
shortTermDebt 6 190M 3 281M 5 617M 3 188M 2 923M 4 400M 2 132M
taxPayables 0 1 371M 1 458M 1 526M 1 209M 942M 1 287M
deferredRevenue 0 4 224M 3 865M 3 791M 0 1 344M 0
otherCurrentLiabilities 16 093M 11 498M 11 167M 10 102M 12 968M 13 106M 14 203M
totalCurrentLiabilities 25 822M 22 262M 23 462M 20 150M 19 085M 21 890M 18 930M
longTermDebt 49 487M 38 183M 33 650M 35 998M 36 448M 36 317M 36 966M
deferredRevenueNonCurrent 0 300M 316M 305M 308M 283M 296M
deferredTaxLiabilitiesNonCurrent 442M 338M 399M 751M 1 568M 2 166M 2 881M
otherNonCurrentLiabilities 6 732M 4 591M 4 374M 4 255M 4 986M 5 046M 41 805M
totalNonCurrentLiabilities 56 661M 43 412M 38 739M 41 309M 43 310M 43 812M 46 532M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 0 1 692M 1 663M 1 510M 1 541M 1 397M 1 012M
totalLiabilities 82 483M 65 674M 62 201M 61 459M 62 395M 65 702M 65 462M
preferredStock 0 0 0 0 0 0 0
commonStock 292M 292M 292M 292M 292M 292M 292M
retainedEarnings 15 640M 28 766M 28 218M 27 449M 26 568M 25 503M 24 675M
accumulatedOtherComprehensiveIncomeLoss -1 400M -1 546M -1 286M -1 387M -1 368M -1 281M -841M
othertotalStockholdersEquity 1 958M 1 918M 1 774M 5 619M 6 332M 6 547M 8 545M
totalStockholdersEquity 16 490M 29 430M 28 998M 31 973M 31 824M 31 061M 32 671M
totalEquity 16 548M 29 485M 29 062M 32 030M 31 824M 31 061M 32 671M
totalLiabilitiesAndStockholdersEquity 99 031M 95 159M 91 263M 93 489M 94 281M 96 820M 98 133M
minorityInterest 58M 55M 64M 57M 62M 57M 0
totalLiabilitiesAndTotalEquity 99 031M 95 159M 91 263M 93 489M 94 281M 96 820M 98 133M
totalInvestments 340M 2 879M 171M 358M 2 279M 2 317M 3 252M
totalDebt 55 677M 41 464M 39 267M 39 186M 39 371M 40 717M 39 098M
netDebt 46 347M 30 000M 31 753M 30 814M 30 376M 31 594M 31 364M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BMY BMY BMY BMY BMY BMY BMY
reportedCurrency USD USD USD USD USD USD USD
cik 14 272 14 272 14 272 14 272 14 272 14 272 14 272
fillingDate 2024-04-25 2024-02-13 2023-10-26 2023-07-27 2023-04-27 2023-02-14 2022-10-26
acceptedDate 2024-04-25 12:38:46 2024-02-13 11:54:06 2023-10-26 12:33:30 2023-07-27 12:28:24 2023-04-27 11:56:52 2023-02-14 16:24:27 2022-10-26 11:37:24
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -11 908M 1 762M 1 934M 2 077M 2 267M 2 025M 1 608M
depreciationAndAmortization 2 532M 2 464M 2 435M 2 432M 2 429M 2 521M 2 588M
deferredIncomeTax -711M -1 327M -327M -1 086M -548M -624M -645M
stockBasedCompensation 0 127M 132M 137M 122M 119M 115M
changeInWorkingCapital 0 855M 291M -1 700M -1 360M -458M 21M
accountsReceivables 479M 536M -659M -2 184M -175M -106M -557M
inventory -218M -197M -256M -16M -282M -41M -16M
accountsPayables 300M 444M -268M -165M 187M 405M -300M
otherWorkingCapital 0 72M 1 474M 665M -1 090M -716M 894M
otherNonCashItems 0 371M 286M 27M 60M -277M 0
netCashProvidedByOperatingActivities 2 834M 4 252M 4 751M 1 887M 2 970M 3 306M 3 687M
investmentsInPropertyPlantAndEquipment -284M -330M -342M -259M -278M -346M -247M
acquisitionsNet -20 053M -340M -79M 10M 149M 374M -3 855M
purchasesOfInvestments -274M -717M -502M -355M -200M -26M -274M
salesMaturitiesOfInvestments 752M 41M 513M 275M 119M 1 211M 1 480M
otherInvestingActivites 241M -435M 258M 0 0 0 815M
netCashUsedForInvestingActivites -19 618M -1 346M -410M -329M -210M 1 213M -2 081M
debtRepayment 0 -2 000M -10M -239M -1 640M -11 431M -2 785M
commonStockIssued 0 -10M 10M 0 0 0 0
commonStockRepurchased 0 0 -4 000M -905M -250M -2 416M -585M
dividendsPaid 0 -1 160M -1 191M -1 197M -1 196M -1 145M -1 154M
otherFinancingActivites 15 856M 4 127M 31M 168M 36M 11 746M -19M
netCashUsedProvidedByFinancingActivities 14 644M 967M -5 160M -2 173M -3 050M -3 246M -4 543M
effectOfForexChangesOnCash -45M 78M -38M -8M 13M 95M -66M
netChangeInCash -2 185M 3 951M -857M -623M -277M 1 368M -3 003M
cashAtEndOfPeriod 9 334M 11 519M 7 568M 8 425M 9 048M 9 325M 7 957M
cashAtBeginningOfPeriod 11 519M 7 568M 8 425M 9 048M 9 325M 7 957M 10 960M
operatingCashFlow 2 834M 4 252M 4 751M 1 887M 2 970M 3 306M 3 687M
capitalExpenditure -284M -330M -342M -259M -278M -346M -247M
freeCashFlow 2 550M 3 922M 4 409M 1 628M 2 692M 2 960M 3 440M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-02 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2022 q4)
2022 q3
2022-10-26 ET (fiscal 2022 q3)
2022 q2
2022-07-27 ET (fiscal 2022 q2)
2022 q1
2022-04-29 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-26 10:59 ET
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2024-04-25 10:59 ET
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
2024-04-22 10:59 ET
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
2024-04-08 15:30 ET
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
2024-04-06 17:15 ET
 Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
2024-04-06 17:15 ET
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
2024-04-05 13:05 ET
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
2024-04-03 00:08 ET
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
2024-04-02 10:59 ET
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
2024-04-01 11:30 ET
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
2024-03-28 20:05 ET
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
2024-03-28 20:01 ET
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
2024-03-26 10:59 ET
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
2024-03-25 12:00 ET
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
2024-03-20 20:45 ET
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
2024-03-20 10:59 ET
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
2024-03-19 10:59 ET
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign
2024-03-18 13:52 ET
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
2024-03-18 12:44 ET
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
2024-03-15 22:27 ET
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
2024-03-15 01:35 ET
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2024-03-11 20:16 ET
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
2024-03-07 19:23 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2024-03-01 21:16 ET
Bristol Myers Squibb Announces Dividend
2024-02-29 11:59 ET
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
2024-02-26 21:16 ET
Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
2024-02-26 13:35 ET
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
2024-02-23 11:59 ET
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
2024-02-23 11:59 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
2024-02-20 11:59 ET
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
2024-02-15 00:57 ET
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
2024-02-14 21:16 ET
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
2024-02-14 11:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
2024-02-13 13:00 ET
VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
2024-02-12 11:59 ET
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
2024-02-07 11:59 ET
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
2024-02-05 14:00 ET
Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
2024-02-05 11:59 ET
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
2024-02-02 11:59 ET
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
2024-01-30 11:59 ET
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
2024-01-27 15:00 ET
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
2024-01-26 12:13 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
2024-01-23 13:30 ET
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
2024-01-22 22:05 ET
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
2024-01-22 22:00 ET
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
2024-01-20 15:00 ET
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
2024-01-17 11:59 ET
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
2024-01-02 11:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
2023-12-26 12:13 ET
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
2023-12-26 11:59 ET
 Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
2023-12-22 14:13 ET
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
2023-12-22 11:59 ET
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
2023-12-22 11:59 ET
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
2023-12-20 21:16 ET
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
2023-12-15 21:54 ET
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
2023-12-15 11:59 ET
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
2023-12-14 12:00 ET
Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb
2023-12-12 02:00 ET
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
2023-12-12 01:30 ET
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
2023-12-12 00:30 ET
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
2023-12-11 21:15 ET
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
2023-12-11 02:26 ET
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
2023-12-09 22:00 ET
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
2023-12-07 11:59 ET
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
2023-12-07 11:30 ET
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
2023-12-06 21:16 ET
Bristol Myers Squibb Announces Dividend Increase
2023-12-05 11:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
2023-11-28 11:30 ET
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
2023-11-20 11:59 ET
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
2023-11-16 00:20 ET
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
2023-11-09 21:18 ET
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
2023-11-09 15:14 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2023-11-08 14:00 ET
Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
2023-11-06 11:59 ET
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
2023-11-02 15:34 ET
Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
2023-11-02 10:59 ET
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
2023-10-31 22:25 ET
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
2023-10-31 00:19 ET
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
2023-10-26 10:59 ET
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
2023-10-24 10:59 ET
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
2023-10-19 10:59 ET
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
2023-10-18 20:15 ET
The Robert A. Winn Diversity in Clinical Trials Award Announces Third Group of Physicians in Program to Increase Diversity in Clinical Trials
2023-10-17 19:51 ET
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
2023-10-17 19:48 ET
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
2023-10-17 19:23 ET
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
2023-10-14 01:18 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma¹
2023-10-12 11:15 ET
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
2023-10-11 22:01 ET
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
2023-10-11 11:01 ET
Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program
2023-10-11 06:01 ET
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
2023-10-06 10:30 ET
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
2023-09-26 10:59 ET
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
2023-09-22 10:59 ET
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
2023-09-20 10:59 ET
Bristol Myers Squibb Announces Dividend
2023-09-17 23:57 ET
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
2023-09-14 12:30 ET
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
2023-09-11 10:59 ET
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
2023-09-09 22:01 ET
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
2023-09-07 11:00 ET
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
2023-09-01 10:59 ET
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-29 02:00 ET
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
2023-08-28 15:26 ET
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
2023-08-28 12:00 ET
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
2023-08-25 14:22 ET
Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
2023-08-23 11:55 ET
Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments
2023-08-22 20:18 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma  
2023-08-21 10:59 ET
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
2023-08-16 14:19 ET
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
2023-08-10 11:01 ET
Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts
2023-08-10 10:59 ET
Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements
2023-08-08 10:59 ET
Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
2023-07-27 10:59 ET
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
2023-07-21 10:59 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
2023-07-12 10:59 ET
Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White
2023-07-11 10:59 ET
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial
2023-06-29 10:59 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%
2023-06-28 12:00 ET
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
2023-06-26 20:01 ET
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
2023-06-17 09:30 ET
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023
2023-06-16 00:23 ET
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
2023-06-14 20:16 ET
Bristol Myers Squibb Announces Dividend
2023-06-08 20:16 ET
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
2023-06-08 10:59 ET
Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023
2023-06-05 16:12 ET
MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
2023-06-04 12:00 ET
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
2023-06-01 10:59 ET
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
2023-05-31 10:59 ET
Bristol Myers Squibb to Hold R&D Day on September 14
2023-05-30 13:24 ET
Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
2023-05-30 10:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
2023-05-26 12:10 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
2023-05-25 21:05 ET
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
2023-05-25 21:00 ET
Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
2023-05-25 10:59 ET
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
2023-05-22 15:01 ET
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
2023-05-11 17:41 ET
Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023
2023-05-03 10:59 ET
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
2023-05-02 10:59 ET
Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
2023-05-01 11:05 ET
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
2023-05-01 10:59 ET
Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
2023-04-27 10:59 ET
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
2023-04-26 20:14 ET
Bristol Myers Squibb Announces Leadership Transition Plan
2023-04-26 18:42 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
2023-04-26 10:59 ET
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
2023-04-20 09:00 ET
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
2023-04-17 10:59 ET
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
2023-04-11 11:04 ET
Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development
2023-03-31 12:07 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
2023-03-30 13:10 ET
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
2023-03-28 10:59 ET
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
2023-03-20 11:00 ET
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
2023-03-15 10:59 ET
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
2023-03-09 11:59 ET
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
2023-03-03 21:16 ET
Bristol Myers Squibb Announces Dividend
2023-03-03 13:00 ET
Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)
2023-03-03 11:59 ET
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
2023-03-02 11:59 ET
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
2023-02-28 11:59 ET
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
2023-02-28 11:59 ET
Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference
2023-02-27 11:59 ET
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
2023-02-17 15:00 ET
Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial
2023-02-16 12:00 ET
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its Symptoms
2023-02-10 16:13 ET
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
2023-02-03 11:59 ET
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
2023-02-02 11:59 ET
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
2023-01-27 12:05 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
2023-01-27 11:59 ET
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
2023-01-26 11:59 ET
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
2023-01-19 13:30 ET
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen’s Commitment of $8 Million
2023-01-03 12:05 ET
Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference
2023-01-03 11:59 ET
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
2022-12-15 11:59 ET
Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023
2022-12-12 11:59 ET
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio
2022-12-08 21:16 ET
Bristol Myers Squibb Announces Dividend Increase
2022-11-29 13:00 ET
Envisagenics Announces Research Collaboration with Bristol Myers Squibb
2022-11-21 11:59 ET
Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
2022-11-09 11:59 ET
Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
2022-11-08 17:10 ET
Lung Cancer Is Personal: Interview With Lee James
2022-11-02 10:59 ET
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
2022-11-01 17:55 ET
A Beacon of Hope
2022-10-31 10:59 ET
Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
2022-10-27 12:30 ET
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
2022-10-26 06:00 ET
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
2022-10-25 23:31 ET
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022 
2022-10-25 18:20 ET
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program
2022-10-25 17:04 ET
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program
2022-10-24 19:00 ET
Empowering Psoriasis Patients Through Mental Health Support
2022-10-24 10:59 ET
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
2022-10-21 10:59 ET
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
2022-10-19 20:30 ET
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
2022-10-07 10:59 ET
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
2022-10-04 11:00 ET
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
2022-09-16 20:15 ET
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
2022-09-15 10:59 ET
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial
2022-09-14 20:16 ET
Bristol Myers Squibb Announces Dividend
2022-09-10 06:30 ET
Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
2022-09-10 02:38 ET
  U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
2022-09-07 11:00 ET
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
2022-09-07 10:59 ET
Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022
2022-09-06 10:59 ET
Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-09-05 10:59 ET
Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
2022-08-31 10:59 ET
Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference
2022-08-28 07:36 ET
Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy
2022-08-17 12:31 ET
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
2022-08-16 10:59 ET
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
2022-08-10 10:45 ET
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
2022-08-03 20:16 ET
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights
2022-07-29 10:59 ET
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
2022-07-27 10:59 ET
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
2022-07-22 10:59 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
2022-07-21 10:59 ET
Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow’s Innovators Program to Increase Black Representation in the Healthcare Industry
2022-07-20 10:59 ET
Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities
2022-07-19 10:59 ET
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
2022-06-24 23:05 ET
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
2022-06-24 16:52 ET
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
2022-06-24 16:51 ET
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
2022-06-20 10:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
2022-06-15 20:16 ET
Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
2022-06-15 20:16 ET
Bristol Myers Squibb Announces Dividend
2022-06-08 10:59 ET
Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022
2022-06-07 10:59 ET
Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-06 10:59 ET
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
2022-06-06 10:59 ET
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
2022-06-03 20:59 ET
Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
2022-06-03 10:59 ET
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
2022-06-02 15:01 ET
Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
2022-06-02 10:59 ET
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
2022-06-01 10:59 ET
Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
2022-05-27 22:11 ET
U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
2022-05-26 21:00 ET
Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
2022-05-26 10:59 ET
Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference
2022-05-19 10:59 ET
Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
2022-05-16 10:59 ET
Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
2022-05-13 10:59 ET
LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York
2022-05-12 10:59 ET
New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
2022-05-04 10:59 ET
Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
2022-04-29 10:59 ET
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
2022-04-29 00:01 ET
U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
2022-04-11 15:15 ET
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
2022-04-11 10:59 ET
Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter
2022-04-05 14:33 ET
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
2022-04-05 10:55 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
2022-04-05 10:50 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
2022-04-05 10:45 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
2022-04-03 13:45 ET
Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten
2022-04-02 13:30 ET
Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial
2022-03-29 10:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
2022-03-25 10:59 ET
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
2022-03-21 12:00 ET
Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
2022-03-18 22:29 ET
U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma
2022-03-11 11:59 ET
Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022
2022-03-09 11:59 ET
Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16
2022-03-04 22:44 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
2022-03-02 20:19 ET
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
2022-03-02 02:03 ET
Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers
2022-03-01 21:16 ET
Bristol Myers Squibb Announces Dividend
2022-03-01 18:00 ET
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
2022-02-28 11:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
2022-02-25 11:55 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1...
2022-02-25 11:50 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...
2022-02-25 11:45 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
2022-02-17 17:19 ET
Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
2022-02-17 11:59 ET
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
2022-02-16 11:59 ET
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy
2022-02-15 21:39 ET
Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
2022-02-15 14:04 ET
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
2022-02-09 11:59 ET
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements
2022-02-08 11:59 ET
Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.
2022-02-04 11:59 ET
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
2022-01-28 11:59 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
2022-01-10 13:00 ET
ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors
2022-01-10 11:45 ET
Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference
2022-01-05 14:03 ET
Bristol Myers Squibb Selects ZS To Support Global Commercialization and Analytics Capabilities
2022-01-04 11:59 ET
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
2021-12-17 11:59 ET
Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022
2021-12-15 20:13 ET
U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
2021-12-14 11:59 ET
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
2021-12-13 11:59 ET
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
2021-12-11 13:30 ET
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results
2021-12-03 11:59 ET
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
2021-11-29 11:59 ET
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
2021-11-23 11:59 ET
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
2021-11-19 11:59 ET
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
2021-11-18 11:59 ET
Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
2021-11-15 16:18 ET
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
2021-11-15 12:00 ET
Bristol Myers Squibb Launches Could It Be HCM? Campaign to Increase Awareness of Hypertrophic Cardiomyopathy (HCM), the Most Common Inherited Heart Disease
2021-11-10 11:59 ET
Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference
2021-11-08 11:59 ET
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
2021-11-08 11:59 ET
Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
2021-11-04 14:16 ET
Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
2021-11-03 10:59 ET
Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases
2021-10-27 10:59 ET
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
2021-10-25 10:59 ET
Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)
2021-10-25 10:45 ET
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
2021-10-21 10:59 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …
2021-10-20 10:59 ET
The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained
2021-10-19 04:14 ET
Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)
2021-10-15 10:59 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
2021-10-14 15:52 ET
GRYT Health and Bristol Myers Squibb Team Up to Launch Diversity in Oncology Initiative
2021-10-13 10:59 ET
Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
2021-10-07 10:59 ET
Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
2021-10-01 11:05 ET
Bristol Myers Squibb to Hold Investor Event on November 16
2021-10-01 11:00 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
2021-10-01 10:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
2021-09-30 13:45 ET
Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases
2021-09-27 11:06 ET
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
2021-09-20 10:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
2021-09-17 10:59 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS ≥ 5
2021-09-16 10:59 ET
Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
2021-09-13 11:05 ET
According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types
2021-09-13 10:59 ET
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 Trial
2021-09-11 00:15 ET
Bristol Myers Squibb Shares Research Supporting Correlation Between New York Heart Association Functional Class (NYHA class) and Mortality in Obstructive Hypertrophic Cardiomyopathy
2021-09-09 20:16 ET
Bristol Myers Squibb Announces Dividend
2021-09-08 11:10 ET
Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021
2021-09-08 11:05 ET
More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. to Advance Cancer Research in Seventh Annual Coast 2 Coast 4 Cancer Ride
2021-09-08 10:59 ET
Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers
2021-09-07 10:59 ET
Bristol Myers Squibb to Take Part in Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-23 10:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
2021-08-20 15:45 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
2021-08-19 13:34 ET
Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma
2021-08-17 10:59 ET
EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
2021-08-10 10:59 ET
Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow’s Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry
2021-08-05 16:02 ET
Expert Panel Issues Recommendations for Addressing Inequities in Cancer Care
2021-08-03 11:00 ET
WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland
2021-08-03 11:00 ET
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland
2021-07-30 10:59 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
2021-07-28 10:59 ET
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
2021-07-16 10:59 ET
Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck
2021-06-29 11:06 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
2021-06-25 10:59 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
2021-06-25 10:50 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
2021-06-18 13:34 ET
Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
2021-06-17 22:30 ET
Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
2021-06-17 20:16 ET
Bristol Myers Squibb Announces Dividend
2021-06-11 07:00 ET
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
2021-06-10 20:16 ET
Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience
2021-06-10 11:05 ET
Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021
2021-06-10 10:59 ET
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
2021-06-08 11:00 ET
 NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2021-06-04 10:59 ET
Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference
2021-06-03 21:01 ET
Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
2021-06-02 10:59 ET
Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
2021-06-02 10:59 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
2021-05-27 20:13 ET
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis¹
2021-05-26 10:59 ET
Bristol Myers Squibb to Take Part in Bernstein’s 37th Annual Strategic Decisions Conference
2021-05-25 10:59 ET
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ASCO 2021 Highlights
2021-05-23 15:35 ET
Bristol Myers Squibb Presents New Data at Digestive Disease Week® on Zeposia (ozanimod) Highlighting Clinical Benefits and Safety Profile in Patients with Ulcerative Colitis
2021-05-21 20:16 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
2021-05-20 17:26 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
2021-05-20 10:59 ET
Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
2021-05-19 21:00 ET
Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
2021-05-19 21:00 ET
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
2021-05-19 21:00 ET
Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial
2021-05-19 21:00 ET
Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma
2021-05-19 11:30 ET
Blue Spark Technologies Announces Observational Trial Using TempTraq® Wearable Device in CAR T Patient Monitoring
2021-05-19 08:00 ET
Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb
2021-05-18 10:59 ET
Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference
2021-05-15 16:15 ET
Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology’s 70th Annual Scientific Session
2021-05-12 15:43 ET
Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
2021-05-06 12:03 ET
DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
2021-05-05 10:59 ET
Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
2021-05-03 13:11 ET
Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology’s 70th Annual Scientific Session
2021-04-30 10:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
2021-04-29 10:59 ET
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
2021-04-28 10:59 ET
Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
2021-04-23 14:00 ET
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
2021-04-23 10:51 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
2021-04-23 10:45 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
2021-04-16 17:10 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma....
2021-04-14 20:16 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
2021-04-14 11:30 ET
Pyramid Biosciences Announces Leadership Team Expansion
2021-04-10 12:30 ET
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
2021-04-08 10:59 ET
 CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal...
2021-04-07 07:00 ET
PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration
2021-03-30 12:05 ET
Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
2021-03-30 10:59 ET
Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX Highlights
2021-03-29 10:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
2021-03-25 10:59 ET
Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival
2021-03-19 10:59 ET
U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
2021-03-11 11:59 ET
Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021
2021-03-02 11:59 ET
Bristol Myers Squibb to Participate in Barclays Virtual Global Healthcare Conference
2021-03-01 21:16 ET
Bristol Myers Squibb Announces Dividend
2021-02-26 11:25 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
2021-02-24 12:10 ET
Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference
2021-02-24 11:59 ET
Bristol Myers Squibb Donates $11 Million to Advance Health Equity
2021-02-23 14:00 ET
Bristol Myers Squibb and the American Music Therapy Association Team Up with Ben Platt and Sister-in-Law Courtney Platt to Launch MS in Harmony, a First-of-its-Kind Music Therapy Offering for People Living with Multiple Sclerosis (MS)
2021-02-23 11:59 ET
Bristol Myers Squibb to Participate in Raymond James Virtual 42nd Annual Institutional Investors Conference
2021-02-22 23:15 ET
Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at “Make Whole” Prices
2021-02-19 22:04 ET
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
2021-02-19 02:29 ET
Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
2021-02-08 22:00 ET
Adjuvant Treatment with Opdivo (nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial
2021-02-08 17:12 ET
Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
2021-02-05 21:39 ET
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
2021-02-05 11:59 ET
Bristol Myers Squibb to Participate in Guggenheim’s Virtual Healthcare Talks | 2021 Oncology Day
2021-02-04 11:59 ET
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
2021-02-04 11:30 ET
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
2021-02-03 11:59 ET
Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
2021-02-02 11:59 ET
WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland
2021-02-02 11:59 ET
Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
2021-02-01 11:59 ET
Bristol Myers Squibb Application for Zeposia® (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
2021-01-22 18:18 ET
U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
2021-01-21 11:59 ET
Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)
2021-01-20 11:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
2021-01-20 11:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
2021-01-11 13:30 ET
GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease
2021-01-11 11:59 ET
Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization
2021-01-07 12:00 ET
ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors
2021-01-04 11:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
2021-01-04 11:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
2021-01-04 11:59 ET
Bristol Myers Squibb to Present at J.P. Morgan’s 39th Annual Virtual Healthcare Conference
2021-01-01 11:59 ET
Bristol Myers Squibb Provides Update on Status of Contingent Value Rights
2020-12-28 11:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis
2020-12-23 11:59 ET
Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
2020-12-21 11:59 ET
Bristol Myers Squibb to Announce Results for Fourth Quarter 2020 on February 4, 2021
2020-12-16 11:59 ET
Bristol Myers Squibb Strengthens its Commitment to the Environment with New Corporate Goals
2020-12-11 13:03 ET
Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation
2020-12-11 12:15 ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
2020-12-11 11:59 ET
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) with Cipla
2020-12-10 21:16 ET
Bristol Myers Squibb Announces Dividend Increase
2020-12-09 13:30 ET
Pentwater Solicits Holders of Bristol-Myers Squibb Contingent Value Rights to Provide Consent to Replace Trustee
2020-12-08 12:00 ET
Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab
2020-12-08 11:59 ET
Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry
2020-12-07 21:30 ET
Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission
2020-12-07 15:00 ET
Bristol Myers Squibb Presents Data Evaluating Potential of Liso-cel Across Leukemia and Lymphomas at ASH 2020
2020-12-01 13:17 ET
CEO Spotlight: Portage Biotech CEO Dr. Ian Walters Talks Asset Pipeline, Uplist, and Strategic Initiatives in a $20 Billion Sector
2020-11-24 11:59 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
2020-11-17 13:30 ET
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
2020-11-17 11:59 ET
The Bristol Myers Squibb Foundation and National Medical Fellowships Launch $100 Million Program to Help Increase Diversity and Inclusion in Clinical Trials
2020-11-17 07:03 ET
Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market Engagement
2020-11-16 21:21 ET
Bristol Myers Squibb Provides Regulatory Update on Lisocabtagene Maraleucel (liso-cel)
2020-11-12 13:00 ET
Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product
2020-11-11 21:15 ET
Bristol Myers Squibb to Participate in Wolfe Research’s 2nd Annual Virtual Healthcare Conference
2020-11-11 11:59 ET
Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020
2020-11-10 00:27 ET
Bristol Myers Squibb Prices $7 Billion of Senior Unsecured Notes
2020-11-09 11:59 ET
Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis
2020-11-06 11:59 ET
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
2020-11-05 12:01 ET
Bristol Myers Squibb Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases
2020-11-05 11:59 ET
Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
2020-11-04 11:59 ET
Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
2020-11-03 11:59 ET
Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study
2020-11-02 12:30 ET
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris
2020-10-28 11:00 ET
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
2020-10-26 12:00 ET
Decreases in Americans' Primary Care Visits May Lead to Late Diagnoses of Potentially Serious Conditions¹
2020-10-16 11:45 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
2020-10-10 22:06 ET
Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Adult Patients with Moderate to Severe Ulcerative Colitis
2020-10-07 10:59 ET
Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
2020-10-05 10:30 ET
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
2020-10-02 20:17 ET
Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients
2020-10-02 20:12 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
2020-10-02 10:59 ET
 Bristol Myers Squibb to Host Virtual Investor Event to Discuss Results from Phase 3 True North Trial Evaluating Zeposia® (ozanimod) in Ulcerative Colitis at UEG Week 2020
2020-10-02 10:59 ET
UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026
2020-09-29 10:59 ET
Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia
2020-09-24 20:15 ET
Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial
2020-09-21 20:16 ET
Bristol Myers Squibb Completes Acquisition of Forbius
2020-09-21 16:31 ET
Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting
2020-09-21 16:30 ET
Opdivo (nivolumab) Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers
2020-09-18 11:17 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
2020-09-17 20:16 ET
Bristol Myers Squibb to Announce Results for Third Quarter 2020 on November 5, 2020
2020-09-17 12:03 ET
Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company
2020-09-17 10:59 ET
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr. Reddy’s
2020-09-17 10:15 ET
Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
2020-09-15 11:30 ET
Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate
2020-09-15 10:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for First-line Treatment of Malignant Pleural Mesothelioma
2020-09-10 20:15 ET
Bristol Myers Squibb Announces Quarterly Dividend for Third Quarter 2020
2020-09-10 10:59 ET
Bristol Myers Squibb to Participate in Morgan Stanley’s 18th Annual Global Healthcare Virtual Conference
2020-09-08 10:59 ET
Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need
2020-09-02 10:59 ET
Bristol Myers Squibb to Participate in Citi’s 15th Annual BioPharma Virtual Conference
2020-09-01 16:50 ET
U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
2020-09-01 13:00 ET
Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
2020-08-25 10:59 ET
Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2020-08-24 10:59 ET
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
2020-08-17 10:59 ET
Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
2020-08-12 10:59 ET
Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts
2020-08-11 10:59 ET
CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
2020-08-11 10:59 ET
CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers
2020-08-08 11:00 ET
Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
2020-08-06 10:59 ET
Bristol Myers Squibb Reports Second Quarter 2020 Financial Results
2020-07-30 10:59 ET
Bristol Myers Squibb Board Elects Two New Independent Directors
2020-07-17 10:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)
2020-07-16 10:59 ET
Bristol Myers Squibb Announces Expiration and Final Results of Registered Exchange Offers
2020-07-14 14:00 ET
ReviveMed Announces AI-driven Metabolomics Study with Bristol Myers Squibb
2020-06-26 13:05 ET
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
2020-06-18 10:59 ET
Bristol Myers Squibb to Announce Results for Second Quarter 2020 on August 6, 2020
2020-06-16 10:59 ET
Bristol Myers Squibb Announces Commencement of Registered Exchange Offers
2020-06-11 20:15 ET
Bristol Myers Squibb Announces Dividend
2020-06-10 23:52 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
2020-06-04 10:59 ET
Bristol Myers Squibb to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
2020-06-03 10:59 ET
New Data Reinforce Improved and Durable Clinical Responses of Orencia in Moderate-to-Severe Early Rheumatoid Arthritis Patients with Autoantibodies Linked to More Severe Disease
2020-06-02 10:59 ET
Bristol Myers Squibb Announces Positive Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Patients with Moderate to Severe Ulcerative Colitis
2020-06-01 10:59 ET
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
2020-05-29 10:59 ET
Bristol Myers Squibb to Hold Virtual Three-Part Investor Series
2020-05-27 10:59 ET
Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
2020-05-26 21:48 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
2020-05-22 10:59 ET
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
2020-05-20 10:59 ET
Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases
2020-05-15 19:56 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1%
2020-05-15 12:53 ET
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma
2020-05-13 21:00 ET
Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Limited Chemotherapy Significantly Improves Overall Survival vs. Chemotherapy Alone for Patients with First-Line Metastatic Non-Small Cell Lung Cancer in CheckMate -9LA Study
2020-05-13 21:00 ET
Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20
2020-05-13 21:00 ET
Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy in Metastatic First-Line Non-Small Cell Lung Cancer Patients with PD-L1 ≥1%
2020-05-13 10:59 ET
Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
2020-05-12 10:59 ET
Bristol Myers Squibb to Take Part in the UBS Virtual Global Healthcare Conference
2020-05-12 10:58 ET
GRYT Health and Bristol Myers Squibb Team Up to Launch COVID Advocacy Exchange for Patient Advocates
2020-05-11 10:59 ET
Bristol Myers Squibb Research at ASCO Demonstrates Diverse Approaches in Treating Cancer to Improve Outcomes for Patients
2020-05-07 10:59 ET
Bristol Myers Squibb Reports Strong First Quarter 2020 Financial Results
2020-05-06 10:59 ET
Bristol Myers Squibb Provides Update on Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel)
2020-05-01 10:59 ET
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia
2020-04-30 20:16 ET
Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
2020-04-20 10:59 ET
Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma
2020-04-14 20:16 ET
Bristol Myers Squibb Announces Virtual 2020 Annual Meeting of Shareholders
2020-04-08 10:59 ET
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer
2020-04-07 10:59 ET
Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.
2020-03-31 10:59 ET
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
2020-03-27 15:05 ET
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
2020-03-26 10:59 ET
New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
2020-03-26 10:58 ET
Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020
2020-03-26 10:30 ET
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
2020-03-23 10:59 ET
Bristol-Myers Squibb Postpones April 2, 2020 Investor Day
2020-03-18 10:59 ET
Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development
2020-03-11 10:59 ET
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib
2020-03-09 10:59 ET
Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma
2020-03-03 22:30 ET
Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
2020-03-02 21:16 ET
CORRECTING and REPLACING Bristol‑Myers Squibb Announces Dividend
2020-02-21 11:59 ET
Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer
2020-02-19 11:59 ET
 Bristol-Myers Squibb to Hold Investor Day on April 2
2020-02-15 19:30 ET
Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma
2020-02-15 18:00 ET
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
2020-02-14 11:30 ET
Multinational Inflammatory Bowel Disease Survey Uncovers Striking Differences in Patients’ and Physicians’ Treatment Goals and Disease Management Expectations
2020-02-13 11:59 ET
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma
2020-02-06 12:05 ET
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
2020-01-31 21:16 ET
Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
2020-01-15 11:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
2020-01-07 08:00 ET
Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy  
2020-01-06 21:16 ET
Bristol-Myers Squibb to Present at the 38th Annual J.P. Morgan Healthcare Conference
2020-01-02 11:59 ET
Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference
2019-12-20 11:59 ET
Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma
2019-12-19 11:59 ET
Bristol-Myers Squibb to Announce Results for Fourth Quarter 2019 on February 6, 2020
2019-12-18 21:16 ET
Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA
2019-12-13 12:00 ET
Bristol-Myers Squibb Announces Leadership Changes
2019-12-10 12:30 ET
Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001
2019-12-09 21:30 ET
Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
2019-12-08 21:30 ET
Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting
2019-12-07 21:00 ET
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
2019-12-07 19:00 ET
Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
2019-12-06 21:16 ET
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
2019-12-06 17:05 ET
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
2019-12-05 21:16 ET
Bristol-Myers Squibb Announces Dividend Increase
2019-12-04 11:59 ET
Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant
2019-12-03 12:38 ET
Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes
2019-11-26 11:59 ET
Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights
2019-11-21 11:59 ET
Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes
2019-11-21 11:21 ET
Amgen Completes Acquisition Of Otezla® (apremilast)
2019-11-20 21:16 ET
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
2019-11-20 14:31 ET
Thinking about buying stock in Aurora Cannabis, Advanced Micro Devices, Bristol-Myers Squibb, Nike, or Visa?
2019-11-20 11:58 ET
Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1%
2019-11-19 16:16 ET
Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500
2019-11-15 21:55 ET
Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition
2019-11-15 11:59 ET
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
2019-11-12 11:59 ET
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
2019-11-11 11:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma
2019-11-07 11:59 ET
Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting¹
2019-04-18 21:30 ET
Heat Biologics CEO to Present at the ThinkEquity Conference in New York City
2019-04-17 12:18 ET
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
2019-04-12 14:48 ET
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
2019-04-12 14:33 ET
Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
2019-04-11 10:59 ET
Bristol-Myers Squibb Receives 2019 ENERGY STAR® Partner of the Year – Sustained Excellence Award
2019-04-02 17:00 ET
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients
2019-04-02 12:00 ET
Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019
2019-03-29 17:33 ET
Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
2019-03-29 15:13 ET
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
2019-03-19 10:59 ET
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
2019-03-17 15:45 ET
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
2019-03-13 11:00 ET
PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment
2019-03-07 22:22 ET
Bristol-Myers Squibb Announces Dividend
2019-03-07 11:59 ET
Bristol-Myers Squibb to Announce Results for First Quarter 2019 on April 25, 2019
2019-03-06 21:58 ET
Bristol-Myers Squibb to Take Part in the Barclays 2019 Global Healthcare Conference
2019-03-06 12:30 ET
Starboard Mails Letter with Important Message to All Bristol-Myers Squibb Stockholders
2019-03-06 11:59 ET
Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene
2019-03-05 14:25 ET
Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai
2019-02-28 14:40 ET
Starboard Delivers Open Letter to Bristol-Myers Squibb Stockholders

SEC forms

Show financial reports only

SEC form 10
2024-04-25 12:38 ET
Bristol-Myers Squibb reported for 2024 q1
SEC form 8
2024-04-25 07:47 ET
Bristol-Myers Squibb reported for 2024 q1
SEC form 8
2024-04-25 07:47 ET
Bristol-Myers Squibb published news for 2024 q1
SEC form 8
2024-04-25 07:47 ET
Bristol-Myers Squibb published news for 2024 q1
SEC form 10
2024-04-25 00:00 ET
Bristol-Myers Squibb reported for 2024 q1
SEC form 10
2024-02-13 00:00 ET
Bristol-Myers Squibb reported for 2023 q4
SEC form 8
2024-02-02 00:00 ET
Bristol-Myers Squibb published news for 2023 q4
SEC form 8
2024-02-02 00:00 ET
Bristol-Myers Squibb reported for 2023 q4
SEC form 8
2024-02-02 00:00 ET
Bristol-Myers Squibb published news for 2023 q4
SEC form 10
2023-10-26 12:33 ET
Bristol-Myers Squibb reported for 2023 q3
SEC form 8
2023-10-26 07:44 ET
Bristol-Myers Squibb reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
Bristol-Myers Squibb reported for 2023 q3
SEC form 10
2023-07-27 12:28 ET
Bristol-Myers Squibb reported for 2023 q2
SEC form 6
2023-07-27 07:50 ET
Bristol-Myers Squibb reported for 2023 q2
SEC form 10
2023-07-27 00:00 ET
Bristol-Myers Squibb reported for 2023 q2
SEC form 8
2023-07-27 00:00 ET
Bristol-Myers Squibb reported for 2023 q2
SEC form 6
2023-06-08 15:44 ET
Bristol-Myers Squibb published news for 2023 q1
SEC form 6
2023-06-08 15:43 ET
Bristol-Myers Squibb published news for 2023 q1
SEC form 6
2023-06-08 15:42 ET
Bristol-Myers Squibb published news for 2023 q1
SEC form 10
2023-04-27 00:00 ET
Bristol-Myers Squibb reported for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Bristol-Myers Squibb reported for 2023 q1
SEC form 10
2023-02-14 00:00 ET
Bristol-Myers Squibb reported for 2022 q4
SEC form 8
2023-02-02 00:00 ET
Bristol-Myers Squibb reported for 2022 q4
SEC form 10
2022-10-26 00:00 ET
Bristol-Myers Squibb reported for 2022 q3
SEC form 8
2022-10-26 00:00 ET
Bristol-Myers Squibb reported for 2022 q3
SEC form 10
2022-07-27 00:00 ET
Bristol-Myers Squibb reported for 2022 q2
SEC form 8
2022-07-27 00:00 ET
Bristol-Myers Squibb reported for 2022 q2
SEC form 10
2022-04-29 00:00 ET
Bristol-Myers Squibb reported for 2022 q1
SEC form 8
2022-04-29 00:00 ET
Bristol-Myers Squibb reported for 2022 q1
SEC form 8
2022-04-18 00:00 ET
Bristol-Myers Squibb published news for 2022 q1
SEC form 10
2022-02-09 00:00 ET
Bristol-Myers Squibb published news for 2021 q4
SEC form 8
2022-02-04 00:00 ET
Bristol-Myers Squibb published news for 2021 q4
SEC form 10
2021-10-27 00:00 ET
Bristol-Myers Squibb published news for 2021 q3
SEC form 8
2021-10-27 00:00 ET
Bristol-Myers Squibb published news for 2021 q3
SEC form 10
2021-07-28 00:00 ET
Bristol-Myers Squibb published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
Bristol-Myers Squibb published news for 2021 q2
SEC form 10
2021-04-29 00:00 ET
Bristol-Myers Squibb published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Bristol-Myers Squibb published news for 2021 q1